1079Tip A Phase I First-in-human Study of PRTH-101, an IgG1 Monoclonal Antibody Targeting DDR1, As a Monotherapy and Combined with Pembrolizumab in Patients with Advanced Solid Malignancies
ANNALS OF ONCOLOGY(2023)
Key words
Antigen Presentation
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined